Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,759 total articles
Skeena Resources (SKE) is transitioning from developer to producer at the Eskay Creek gold-silver project. With permits in hand, construction financing completed via a US$750m senior secured notes issuance, and the project ~49% complete, the stock looks positioned to re-rate as production risk recedes. The trade below targets a move toward the 52-w…
OPKO (OPK) trades like a beaten-down biotech but carries a diagnostics franchise and a balance sheet that make a measured long position attractive. With a market cap near $1.02B, EV/sales ~1.8x, improving technicals and upcoming program milestones with Entera Bio, I prefer a long trade sized modestly for recovery upside while protecting against con…
STMicroelectronics (STM) has given back a large chunk of recent gains and is trading near $52.22 after a corrective stretch. The company still benefits from structural growth in automotive microcontrollers, power electronics for EVs, and sensors. With a market cap near $47.4B, positive free cash flow, and improving technical momentum, a disciplined…
Edgewise Therapeutics has moved from a pure binary biotech to a company with optionality: an announced licensing arrangement with Servier should provide non-dilutive capital that extends runway for EDG-7500 and sevasemten. The trade: go long around current levels to capture upside into upcoming pivotal catalysts while protecting against trial and r…
Commercial Metals Company (CMC) looks like a constructive swing trade today. The business is cash-generative, pays a reliable dividend, and is diversifying into precast concrete after a $675M acquisition. Valuation is reasonable with a P/E near 13.7 and EV/EBITDA around 13.5. Technicals are neutral; catalyst flow and improving free cash flow suppor…
Materion (MTRN) looks buyable at current levels after a pullback. The company sells specialized materials for electronics, aerospace and optics; recent wins in gold targets and precision coatings plus a healthy backlog support revenue growth. Valuation is rich versus historical norms but the trade offers a defined entry at $266.61 with a $300 targe…
Cerus operates the INTERCEPT blood-safety platform for platelets and plasma. At a market cap near $600M and trading comfortably off its 52-week low, CERS combines recurring revenue characteristics with a short-interest backdrop and improving technicals that make a focused long swing trade attractive. This is a tactical, mid-term (45 trading days) t…
Super Micro (SMCI) just reported staggering top-line momentum and margin improvement tied to AI server demand, yet the stock trades at a valuation that discounts much of that growth. The trade: a long position sized for high volatility with a clear stop and a $60 target over a 180-trading-day horizon, accepting legal and financing risk as the prima…
Nvidia’s valuation still looks rich on face value, but improving fundamentals (large free cash flow, rock-solid margins) and fresh catalysts around AI infrastructure financing and customer commitments justify a tactical upgrade. Take a mid-term long with a clear stop and target while watching the Aug 26 earnings print and partner deal confirmations…
SK hynix is trading well below its 52-week high after a volatile few weeks of headlines. The company sits on strong margins, sizable cash flow, and leadership in high-bandwidth memory. With a market cap near $1.17 trillion, a forward P/E ~11 and technical indicators showing improving momentum, this trade targets a rebound toward $190 while limiting…
The Timken Company (TKR) is a cash-generative industrial with a sensible balance sheet, steady dividend policy and room for EPS recovery. At an entry near $130, the stock can reach $150 in 180 trading days on modest margin and earnings improvement - a buy that does not depend on a multiple expansion.
JBT Marel's share price has pulled back on macro and execution fears, but the business mix, backlog profile, and recurring aftermarket revenue argue for a bounce. This trade idea lays out a clear entry, stop, and target for a mid-term (45 trading days) recovery while outlining catalysts and risks to monitor.
Geron is moving from development to commercial execution. RYTELO generated $184M in 2025 revenue and management guides $220-240M for 2026, while the company carries enough cash to fund near-term priorities. The Phase 3 program in JAK-inhibitor relapsed/refractory myelofibrosis is the key optionality that could re-rate valuation, but intensifying co…
Nano Labs (NA) trades at $1.92 with a $44.6M market cap, cheap fundamentals (P/E 2.03, P/B 0.42) and improving momentum. Upcoming MOU workstreams, product launches and exec buying make a nimble long trade viable: entry $1.92, target $3.50, stop $1.58.
Netlist (NLST) is riding clear fundamental wins - a $445M patent victory and accelerating data-center revenue - and the market is starting to price in licensing or settlement upside. Technical momentum, elevated short activity and a much higher float-implied market cap create a high-reward, high-risk swing trade. Here’s an actionable entry, stop an…
Meta's stock has pulled back sharply, creating a tradeable opportunity. With a market cap near $1.40T, a PE of 21.4, and renewed AI-related capex tailwinds, a disciplined long from ~$548 targets a 30% climb to $712 over the next 180 trading days. The setup balances valuation, near-term sentiment overshoot, and durable monetization in the Family of …
American Integrity Insurance Group is trading at a steep multiple discount to peers while reporting solid profitability (ROE ~21.6%), meaningful free cash flow ($70.7M) and growing policy counts. The stock shows momentum but is technically extended; this trade buys the fundamental case with a clear entry, stop and target across a 180-trading-day ho…
Rocket Lab (RKLB) is a Strong Buy for disciplined, growth-oriented investors. The upcoming Neutron milestones matter, but the investment case also rests on a $2.3B+ backlog, 60%+ top-line growth, strong liquidity ratios and minimal debt. Valuation is rich on headline multiples, so trade with a clear entry, stop and targets and treat this as a direc…
<p>NetScout Systems (NTCT) is a steady cash-flow generator in network observability and DDoS/cyber mitigation. The stock trades near $38.84 with a market cap roughly $2.8B, an attractive price-to-free-cash-flow of ~10.9 and EV/EBITDA around 12.2. For investors willing to take a mid-term swing, the risk/reward looks favorable: operational tailwinds …
Assurant's mix of Global Lifestyle and Global Housing businesses is delivering steady top-line growth and strong free cash flow. With a market cap around $14.2B, a P/E near 14, and price sitting above key moving averages, the setup favors a long trade over the next 180 trading days. Entry, stop and target are provided with catalysts and a balanced …
Sandisk (SNDK) is trading at growth-like multiples but is delivering growth and cash flow. With investor-day targets and near-term supply tightness for NAND, I like a directional long into $2,250 with a disciplined stop. This is a trade, not a perpetual buy-and-hold.
OmniAb's discovery platform and a string of co-discovery deals have moved the stock above key moving averages. At a market cap near $564M, the company sits in a sweet spot for partnership-driven rerating. This trade targets a mid-term move into the $4.40 area with a tight stop under recent technical support.
Cisco's upgraded $9B AI order target and strong free cash flow make the stock an attractive buy on pullbacks around $112.42. The trade is a long-term directional idea (46-180 trading days) that leans on continued hyperscaler spending for AI infrastructure. The main caveat: margin pressure from promotional pricing and channel inventory could limit u…
Accenture has been punished sharply in 2026, but its scale, AI partnerships, and record bookings argue for a recovery. This trade buys the pullback with a $170 entry, $220 target and $150 stop, aiming for a long-term re-rating as AI becomes a revenue amplifier rather than a job killer.
ARS Pharma has a new CEO implementing a clear two-pronged program: reduce operating burn and accelerate commercial execution for core products. That combination is rare in small-cap biotech: fewer cash worries and the potential for visible revenue acceleration. This trade idea lays out an entry at $3.25, a stop at $2.50 and a primary target of $6.2…
